Revolo advances plans to tackle eosinophilic esophagitis with orphan drug tag
The FDA has granted an orphan drug designation to Revolo’s ‘1104, with plans for a Phase IIb study later this year.
The FDA has granted an orphan drug designation to Revolo’s ‘1104, with plans for a Phase IIb study later this year.
What's Your Reaction?
